Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureYuehua Liang, Xialin Xie
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study
10.1016/j.annonc.2024.11.012 · 2025
Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer
10.1056/nejmoa2402141 · 2024
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
10.1016/s0140-6736(24)02848-4 · 2025
Treatment of metastatic colorectal cancer: ASCO guideline
10.1200/jco.22.01690 · 2023
Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting
10.1016/j.ejca.2023.113433 · 2024
Liver metastases and peritoneal metastases and response to checkpoint inhibitors in metastatic colorectal cancer with microsatellite instability
10.1093/oncolo/oyae249 · 2024
Clinical response to immunotherapy targeting programmed cell death receptor 1/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases
10.1001/jamanetworkopen.2021.18416 · 2021
Liver metastases and immune checkpoint inhibitor efficacy in patients with refractory metastatic colorectal cancer: a secondary analysis of a randomized clinical trial
10.1001/jamanetworkopen.2023.46094 · 2023
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study
10.1016/j.eclinm.2023.101917 · 2023
Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial
10.1001/jamaoncol.2022.7845 · 2023
Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases
10.1016/j.ejca.2023.113437 · 2024
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
10.1038/s41591-024-03083-7 · 2024
Metastatic sites and lesion numbers cooperated to predict efficacy of PD-1 inhibitor-based combination therapy for patients with metastatic colorectal cancer
10.1002/cam4.5959 · 2023
Effect of liver metastases on survival in microsatellite-stable metastatic colorectal cancer treated with immune checkpoint inhibitors
10.1158/2767-9764.crc-25-0690 · 2026
Upfront fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal cancer: updated and overall survival results of the ATEZOTRIBE study
10.1200/jco.23.02728 · 2024
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study
10.1016/j.esmoop.2025.104135 · 2025
Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: final analysis of the randomized, open-label, phase III LEAP-017 study
10.1200/jco.23.02736 · 2024
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
10.1016/j.annonc.2024.03.009 · 2024
The liver-immunity nexus and cancer immunotherapy
10.1158/1078-0432.ccr-21-1193 · 2022
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
10.1038/s41591-020-1131-x · 2021
IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction
10.1016/j.jhep.2023.12.015 · 2024
Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy
10.1073/pnas.2105323118 · 2021
Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level
10.1158/2159-8290.cd-21-0316 · 2022
Immune phenotypic linkage between colorectal cancer and liver metastasis
10.1016/j.ccell.2022.02.013 · 2022
Colorectal cancer metastases in the liver establish immunosuppressive spatial networking between tumor-associated SPP1+ macrophages and fibroblasts
10.1158/1078-0432.ccr-22-2041 · 2023
Peritumoral immune-suppressive mechanisms impede intratumoral lymphocyte infiltration into colorectal cancer liver versus lung metastases
10.1158/2767-9764.crc-23-0212 · 2023
The histological growth patterns in liver metastases from colorectal cancer display differences in lymphoid, myeloid, and mesenchymal cells
10.1002/mco2.70000 · 2024
Molecular characterization of the histopathological growth patterns of colorectal cancer liver metastases by RNA sequencing of targeted samples at the tumor-liver interface
10.1007/s10585-024-10319-w · 2024
Classifying histopathological growth patterns for resected colorectal liver metastasis with a deep learning analysis
10.1093/bjsopen/zrae127 · 2024
Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicentre, single-arm phase II study (ILOC)
10.1016/j.esmoop.2025.105508 · 2025
Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer
10.1056/nejmoa2400634 · 2024
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
10.1038/s41591-024-03250-w · 2024
Immunotherapy in localized colorectal cancer: current practice and future directions
10.1200/edbk-26-520600 · 2026
Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial
10.1016/j.esmogo.2025.100226 · 2025
Prospective study of perioperative circulating tumor DNA dynamics in patients undergoing hepatectomy for colorectal liver metastases
10.1097/sla.0000000000005461 · 2023
Recurrence prediction by circulating tumor DNA in the patient with colorectal liver metastases after hepatectomy: a prospective biomarker study
10.1245/s10434-023-13362-1 · 2023
Personalized circulating tumor DNA monitoring improves recurrence surveillance and management after curative resection of colorectal liver metastases: a prospective cohort study
10.1097/js9.0000000000001236 · 2024
Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2026.03.005 · 2026
Differential cytokine and chemokine expression after ablation vs. resection in colorectal cancer liver metastasis
10.1016/j.sopen.2024.01.005 · 2024
Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases
10.1002/14651858.cd012757.pub2 · 2024
No additional external references are available.